MIAMI - eTradeWire -- NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP) $NRXP has announced a major regulatory achievement that could mark a defining moment in the company's development. On October 30, 2026, NRx announced that the U.S. Food and Drug Administration (FDA) approved its Abbreviated New Drug Application (ANDA) for preservative-free intravenous ketamine, delivering the approval ahead of the agency's previously announced November 10 goal date. This is an important achievement for a company that has spent considerable time advancing its formulation, manufacturing capabilities, regulatory submissions, and commercial preparations. With FDA approval now secured and commercial manufacturing supply already on hand, NRx is positioned to move toward supplying American hospitals and clinics with its preservative-free ketamine product. The announcement also brings together several developments achieved during the past six months, including manufacturing process validation, encouraging two-year stability results, an approximately $11.25 million DARPA contract, advanced robotic brain stimulation initiatives, and continued development of its broader pharmaceutical pipeline. For investors following the neuroscience and mental health sector, this is an especially significant development in the NRx story.

FDA Approval Arrives Ahead of Schedule: A Major Milestone for NRXP

The October 30 announcement is the headline achievement. The FDA has approved NRx's ANDA for preservative-free ketamine ahead of its November 10 GDUFA goal date. This approval clears an important regulatory hurdle for the company's commercial ketamine product and allows NRx to move forward with product labeling and preparations to supply healthcare providers.

One of the distinguishing characteristics of the company's formulation is the absence of benzethonium chloride (BZT), an antimicrobial preservative found in existing ketamine injection products discussed in the company's announcement. NRx has focused on developing a sterile, preservative-free presentation that maintains product purity, potency, and sterility without relying on this ingredient.

The company believes this offers an important opportunity for hospitals and clinics, particularly given the ongoing challenges surrounding the supply of sterile injectable medicines. Ketamine injection has experienced supply shortages, and NRx has emphasized the importance of establishing dependable domestic manufacturing capacity.

CEO Jonathan Javitt, MD, MPH, highlighted the opportunity to bring the product to market and provide physicians and patients with another option for repeat treatments without the preservative-related concerns identified by the company.

The approval also represents an important achievement for American pharmaceutical manufacturing. NRx worked with Nephron Pharmaceuticals in West Columbia, South Carolina, to establish domestic production using modern blow-fill-seal manufacturing technology. The company believes this approach demonstrates the potential to bring additional sterile injectable pharmaceutical manufacturing back to the United States.

Commercial Manufacturing Is Already Prepared

More on eTradeWire News

• Capasight brings delivery intelligence into Jira, Azure DevOps and monday.com
• Cleveland Factory Worker Seeks Funding for AI-Readable Archive Exploring Advanced AI Restraint and Human Survival
• ACCENT New Orleans DMC Welcomes Campbell McCoy as Sales & Event Communications Coordinator
• California Crashes After Dark Are Twice as Likely to Be Fatal, New Study Finds
• Premium Publishing USA Provides Full Publishing Support for First-Time

One of the most encouraging developments leading into the FDA decision was NRx's October 19 announcement confirming completion of three commercial process validation lots of preservative-free ketamine.

The company reported that all three lots were manufactured under commercial conditions in compliance with the process validation requirements of FDA Good Manufacturing Practices. This represented an important manufacturing milestone ahead of the anticipated regulatory decision.

NRx also announced completion of two-year, real-time room-temperature stability testing. According to the company, the results demonstrated no deterioration in purity, potency, or sterility without the need for preservatives.

The company believes these results are consistent with a potential labeled shelf life of three years or longer, subject to applicable regulatory requirements.

Importantly, NRx reported that commercially releasable drug supply was already on hand pending ANDA approval. With the October 30 approval now announced, the company has moved beyond the regulatory uncertainty that surrounded its immediate ketamine commercialization opportunity.

The combination of FDA approval, completed manufacturing validation, and available commercial supply gives NRx an important foundation as it moves toward commercialization.

An $11.25 Million DARPA Contract Creates Another Major Opportunity

While the FDA approval is understandably receiving significant attention, NRx has another important development that could contribute to its longer-term growth.

On September 30, NRx Defense Systems announced an approximately $11.18 million prime contract from the Defense Advanced Research Projects Agency (DARPA). The October 30 corporate announcement subsequently referenced an approximately $11.25 million contract to conduct a Phase 3 trial evaluating NRX-101 in combination with robotic neuronavigated transcranial magnetic stimulation.

The SPARC-TMS program is designed to investigate a single-day treatment approach for patients with treatment-resistant depression.

The initiative brings together NRx Defense Systems, HOPE Therapeutics, McLean Hospital, Arizona State University, Zeta Surgical Systems, and Neurocare of America.

This is an important development because it combines an investigational pharmaceutical candidate with advanced brain stimulation technology and a government-funded clinical research program.

The contract has an 18-month performance period, with funding tied to program milestones and additional funding subject to applicable appropriations and contract options.

If successful, the research could provide an additional development pathway for NRX-101 and potentially support further opportunities in the treatment of difficult-to-treat depression.

HOPE Therapeutics and Robotic TMS Expand the Company's Reach

NRx's HOPE Therapeutics subsidiary is another important part of the company's broader strategy.

In September, NRx announced preparations to deploy Zeta Surgical's FDA-cleared robotic TMS navigation system at HOPE's Florida clinics.

The technology is designed to assist clinicians with precise TMS positioning through advanced navigation software. This complements NRx's interest in combining pharmaceutical development with technology-enabled psychiatric treatment.

The relationship between HOPE Therapeutics, robotic TMS, and the SPARC-TMS clinical research program gives NRx an opportunity to connect its pharmaceutical pipeline with an expanding interventional psychiatry platform.

More on eTradeWire News

• Ten Ten Ten Announces Maximizing Quality Performance, a Value-Based Care Implementation Guide
• YMCA Launches Holiday Food & Toy Drive
• TST Announces Seine River Cruise Fare Reduction to $995 for December Paris Holiday Getaway
• Hunter's Garage Teams Up With The Small Batch for a Free Thanksgiving Meal
• Georgia's Largest Vintage Disney Collectibles Store Celebrates Grand Opening Saturday, November 7

Rather than relying on a single product opportunity, the company is developing several interconnected initiatives in mental health treatment and neurological research.

NRX-100 and NRX-101: A Broader Pharmaceutical Pipeline

NRx's development strategy includes two important pharmaceutical programs.

NRX-100 is preservative-free intravenous ketamine. The newly announced ANDA approval represents a major achievement for its commercial product pathway. Separately, the company is pursuing an NDA for potential treatment claims involving depression and suicidal ideation, including bipolar depression. NRX-100 has received FDA Fast Track Designation for this development program.

NRX-101 is an investigational oral combination of D-cycloserine and lurasidone. The company is developing it for serious depression-related conditions, including suicidal bipolar depression, and has reported FDA Breakthrough Therapy Designation for this program.

These are separate development opportunities with different regulatory requirements. The October 30 ANDA approval does not constitute approval of the separate NRX-100 NDA or NRX-101.

Nevertheless, the combination of an approved commercial ketamine product and additional investigational programs gives NRx multiple opportunities to pursue its broader mission in neuroscience and mental health.

Financial Preparation and the Next Stage of Growth

In its August 17 second-quarter 2026 corporate update, NRx reported approximately $26.7 million in cash and cash equivalents as of June 30, 2026, and approximately $22.3 million in gross proceeds from an underwritten public offering.

The company also described its commercial preparation efforts, including manufacturing plans and launch inventory development.

Now that the preservative-free ketamine ANDA has received FDA approval, investors will be watching for further information about commercial distribution, customer relationships, initial orders, revenue generation, and the financial resources required to support expansion.

The approval represents an important regulatory achievement, while actual commercial performance will depend on execution, market adoption, manufacturing, distribution, and reimbursement considerations.

The Bottom Line: A Landmark Day for NRx Pharmaceuticals

October 30, 2026, will stand out as an important date in the NRx Pharmaceuticals story. FDA approval of preservative-free ketamine ahead of the November 10 goal date represents a major accomplishment following months of regulatory work, manufacturing preparation, and stability testing.

The company now has an approved ANDA for its preservative-free ketamine product, completed commercial process validation, two-year stability results, and manufactured commercial supply. These achievements provide an important foundation for its next phase of development.

Beyond ketamine, the approximately $11.25 million DARPA research contract, SPARC-TMS initiative, HOPE Therapeutics platform, and NRX-101 development program offer additional opportunities to watch.

For investors, the focus now shifts toward commercialization and the company's ability to translate its regulatory and research achievements into sustainable business growth.

NRx Pharmaceuticals has reached a significant milestone, and its next chapter will be defined by execution. With FDA approval now secured for preservative-free ketamine, the company has an important opportunity to establish its position in the sterile injectable pharmaceutical market while continuing to pursue its broader ambitions in neuroscience and mental health.

For more information on $NRXP visit: https://www.nrxpharma.com/ and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/

Media Contact
Company Name: NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
Contact Person: Brian Korb, Managing Partner, astr partners
Email: brian.korb@astrpartners.com
Phone: (917) 653-5122
Country: United States

DISCLAIMER: https://corporateads.com/disclaimer/

Disclosure listed on the CorporateAds website